TY  - JOUR

T1  - DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps396

PY  - 2023/02/20

AU  - Niazi T

AU  - McBride SM

AU  - Williams S

AU  - Davis ID

AU  - Stockler MR

AU  - Martin AJ

AU  - Chung HT

AU  - Roncolato F

AU  - Ebacher A

AU  - Khoo E

AU  - Martin J et al

ED  - 

DO  - DOI: 10.1200/jco.2023.41.6_suppl.tps396

PB  - American Society of Clinical Oncology (ASCO)

VL  - 41

IS  - 6_suppl

SP  - TPS396

EP  - TPS396

Y2  - 2024/10/23

ER  -